Evidence map›Paper›PMID 41634948›Full record

ReviewJournal of peptide science : an official publication of the European Peptide Society2026

Bismuth Bicycles.

Saan Voss, Amin Sagar, Arnaud Tiberghien, Richard J L Hughes, Liuhong Chen, Inmaculada Rioja, Mark Frigerio, Michael J Skynner, David R Spring

Abstract readReview
In one paragraph

Review in Journal of peptide science : an official publication of the European Peptide Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Bismuth Bicycles.Journal of peptide science : an official publication of the European Peptide Society · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Saan VossYusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.ORCID https://orcid.org/0000-0002-0108-0888
Amin SagarBicycle Therapeutics, Portway Building, Granta Park, Cambridge, UK.ORCID https://orcid.org/0000-0002-6207-9557
Arnaud TiberghienBicycle Therapeutics, Portway Building, Granta Park, Cambridge, UK.ORCID https://orcid.org/0000-0002-2936-0515
Richard J L HughesBicycle Therapeutics, Portway Building, Granta Park, Cambridge, UK.ORCID https://orcid.org/0009-0000-2564-5444
Liuhong ChenBicycle Therapeutics, Portway Building, Granta Park, Cambridge, UK.ORCID https://orcid.org/0000-0003-1776-3146
Inmaculada RiojaBicycle Therapeutics, Portway Building, Granta Park, Cambridge, UK.ORCID https://orcid.org/0000-0002-0533-2253
Mark FrigerioBicycle Therapeutics, Portway Building, Granta Park, Cambridge, UK.ORCID https://orcid.org/0000-0002-5954-0488
Michael J SkynnerBicycle Therapeutics, Portway Building, Granta Park, Cambridge, UK.ORCID https://orcid.org/0000-0001-6586-9055
David R SpringYusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.ORCID https://orcid.org/0000-0001-7355-2824

Funding

UK Research and Innovation 10090595
6 · The paper itself

Abstract

Bicyclic peptides are emerging as next generation therapeutics by combining the affinity and specificity of antibodies with the synthetic convenience of small molecules. Phage-encoded libraries of bicyclic peptides enable the discovery of high-affinity molecules against virtually any protein target. The generation of bicyclic peptides that advanced into clinical development involves the reaction of three cysteines in a peptide to a C

Indexed as

BismuthPeptides, CyclicHumansPeptide LibraryBismuthPeptide LibraryPeptides, Cyclic

Identifiers

PMID41634948
PMCPMC12868410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.